Inflammatix Secures $57M to Advance Novel Test for Sepsis and Infectious Diseases nextdigitalhealth.com

Inflammatix, a California-based healthcare technology company specializing in molecular diagnostic tests for clinical and public health has secured $57 million in Series E funding round.

The company will use the new capital to support regulatory approval application and commercialization of its innovative rapid blood test for sepsis and acute infections.